Previous 10 | Next 10 |
"Having looked at the data," it is "quite promising", NIH's Dr. Anthony Fauci said in an interview on NPR of Moderna's (NASDAQ: MRNA ) new efforts and it's Phase 1 trial. More news on: Moderna, Inc., SPDR S&P 500 Trust ETF, News on the U.S. economy, News on ETFs, Read m...
It's been a monumental few days for Moderna (NASDAQ: MRNA) . Its stock experienced a significant spike on Monday after the pharma giant announced that phase 1 trials for its prospective COVID-19 vaccine, mRNA-1273, showed promising interim results. Shares closed almost 20% higher on Mond...
Moderna (NASDAQ: MRNA) shares soared 20% in one trading session on Monday after the company reported positive interim data from its coronavirus vaccine clinical trial. The data is indeed promising -- across all participants in two dosage groups, levels of binding antibodies were at...
Shares of Moderna (NASDAQ: MRNA) fell nearly 9% on Thursday, continuing a downward trend that began soon after the biotechnology company's recent stock sale. Moderna's stock soared on Monday after it released positive data from its phase 1 study for mRNA-1273, its coronavirus vaccine...
Moderna CEO Bancel served investors lemonade before the market opened on Monday at the interim phase 1 SARS-CoV-2 vaccine data conference. As of Tuesday’s market close the stock has nearly filled in Monday’s gap up. Bancel’s vague responses to very appropriate questions fr...
I started writing this article a few days ago, but Tuesday's close is a great example of how strange this market is. Tuesday, the market is up the entire day 70bps or so. Not unusual of late. Then, it turns out Moderna ( MRNA ), a company that's working on a vaccine, may have misrepresented i...
In a note, Evercore ISI's Joshua Schimmer says Moderna's (NASDAQ: MRNA ) COVID-19 vaccine, mRNA-1273, is unlikely to be the best of the bunch but may wind up being "good enough" to get the first regulatory nod, adding that other candidates appear poised to offer higher immunogenicity, fewer ...
Many experts think that until an effective vaccine for the SARS-CoV-2 coronavirus is developed and widely deployed, the U.S. economy won't be able to truly return to normalcy. They're probably right. While air travel passenger volume has very gradually started to make a comeback from the extrem...
NEW ORLEANS, May 20, 2020 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Moderna, Inc. (NasdaqGS: MRNA). Such investors are...
Stocks continue their unlikely recovery in the face of skepticism among participants who see more trouble ahead for the global economy. The thinking of many analysts and observers is that the 34% rebound in the S&P 500 Index (SPX) has been nothing more than a massive bear market rally that...
News, Short Squeeze, Breakout and More Instantly...
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a...
On CNBC's “Mad Money Lightning Round,” Jim Cramer believes in Moderna, Inc. (NASDAQ:MRNA). On May 14, Evercore ISI Group analyst C...
2024-05-14 06:35:00 ET Investors have put their hopes in Moderna 's (NASDAQ: MRNA) next potential product, a respiratory syncytial virus (RSV) vaccine. That's because it represents a new revenue stream for a company that until now has relied on just one product, and a product strugg...